<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087009</url>
  </required_header>
  <id_info>
    <org_study_id>03-095</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-03095</secondary_id>
    <nct_id>NCT00087009</nct_id>
  </id_info>
  <brief_title>Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation</brief_title>
  <official_title>Phase I Study of Oral ß-Glucan and Intravenous Rituximab Among Children and Adolescents With Relapsed CD20-Positive Lymphoma or Leukemia, or Post-Transplant Lymphoproliferative Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill&#xD;
      them or deliver cancer-killing substances to them without harming normal cells. Beta-glucan&#xD;
      may increase the effectiveness of rituximab by making cancer cells more sensitive to the&#xD;
      monoclonal antibody.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan when&#xD;
      given together with rituximab in treating young patients with relapsed or progressive&#xD;
      lymphoma or leukemia or with lymphoproliferative disorder related to donor stem cell&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of beta-glucan when given in combination with&#xD;
           rituximab in pediatric patients with relapsed or progressive CD20-positive lymphoma or&#xD;
           leukemia or post-allogeneic stem cell transplant-related lymphoproliferative disorder.&#xD;
&#xD;
        -  Determine the toxicity of this regimen, with special emphasis on the degree of B-cell&#xD;
           depletion and immune suppression, in these patients.&#xD;
&#xD;
        -  Determine the effects of beta-glucan on leukocyte-mediated cytotoxic effects in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the antitumor effect of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of beta-glucan. Patients are assigned to 1 of 2&#xD;
      treatment groups according to diagnosis.&#xD;
&#xD;
        -  Group I (lymphoma or leukemia): Patients receive rituximab IV on days 1, 8, 15, and 22&#xD;
           and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats&#xD;
           every 42 days for 4 courses in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
        -  Group II (post-allogeneic stem cell transplant-related lymphoproliferative disorder):&#xD;
           Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once&#xD;
           daily on days 8-28. Beginning on day 42, patients with responding disease may receive&#xD;
           monthly rituximab prophylaxis until their CD4 cell count is &gt; 200/mm^3.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of beta-glucan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-24 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Accrual&#xD;
  </why_stopped>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once daily on days 8-28. Beginning on day 42, patients with responding disease may receive monthly rituximab prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>beta-glucan</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  B-cell non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
               -  Hodgkin's lymphoma&#xD;
&#xD;
               -  Post-transplant lymphoproliferative disorder (PTLD)&#xD;
&#xD;
               -  Lymphoblastic leukemia&#xD;
&#xD;
          -  CD20-positive disease verified by immunophenotyping at original diagnosis, disease&#xD;
             relapse, or disease progression&#xD;
&#xD;
          -  Refractory to conventional therapy, defined as 1 of the following:&#xD;
&#xD;
               -  Medically refractory HIV-associated NHL&#xD;
&#xD;
               -  Refractory or recurrent lymphoblastic leukemia&#xD;
&#xD;
               -  PTLD&#xD;
&#xD;
               -  In &gt; first relapse or progression of B-cell NHL or Hodgkin's lymphoma&#xD;
&#xD;
          -  Measurable (CT scan or MRI) or evaluable (marrow metastases or circulating&#xD;
             lymphoblasts) disease within 4 weeks after completion of prior systemic (including&#xD;
             systemic steroids) therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Under 22&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 500/mm^3*&#xD;
&#xD;
          -  Platelet count &gt; 10,000/mm^3* NOTE: *Excluding patients with PTLD or CD20-positive&#xD;
             lymphoblastic leukemia&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Hepatic toxicity ≤ grade 2&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Renal toxicity ≤ grade 2&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac toxicity ≤ grade 2&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Pulmonary toxicity ≤ grade 2&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  Human anti-mouse antibody (HAMA) ≤ 1,000 units/mL&#xD;
&#xD;
          -  Human anti-chimeric antibody titer negative&#xD;
&#xD;
          -  No active, life-threatening infections except Epstein-Barr virus-associated&#xD;
             lymphoproliferative disorder&#xD;
&#xD;
          -  No history of allergy to mouse proteins&#xD;
&#xD;
          -  No history of allergy to rituximab or other chimeric monoclonal antibodies&#xD;
&#xD;
          -  No history of allergy to beta-glucan or oats, barley, mushrooms, or yeast&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Grade 3 hearing deficit allowed&#xD;
&#xD;
          -  Gastrointestinal toxicity ≤ grade 2&#xD;
&#xD;
          -  Neurologic toxicity ≤ grade 2&#xD;
&#xD;
          -  No severe major organ toxicity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior rituximab&#xD;
&#xD;
          -  No prior mouse antibodies&#xD;
&#xD;
          -  No prior chimeric antibodies&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shakeel Modak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nai-Kong V. Cheung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trudy N. Small, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanya Trippett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>March 18, 2013</last_update_submitted>
  <last_update_submitted_qc>March 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post-transplant lymphoproliferative disorder</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

